vs
Side-by-side financial comparison of AIM ImmunoTech Inc. (AIM) and ARGENX SE (ARGX). Click either name above to swap in a different company.
ARGENX SE is the larger business by last-quarter revenue ($2.5B vs $21.0K, roughly 117785.4× AIM ImmunoTech Inc.). ARGENX SE runs the higher net margin — 35.5% vs -19881.0%, a 19916.4% gap on every dollar of revenue. On growth, ARGENX SE posted the faster year-over-year revenue change (83.2% vs -53.3%).
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
AIM vs ARGX — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $21.0K | $2.5B |
| Net Profit | $-4.2M | $877.2M |
| Gross Margin | — | 89.5% |
| Operating Margin | -14057.1% | 28.9% |
| Net Margin | -19881.0% | 35.5% |
| Revenue YoY | -53.3% | 83.2% |
| Net Profit YoY | 30.0% | 1.3% |
| EPS (diluted) | $-6.46 | $13.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.0K | $2.5B | ||
| Q3 25 | $26.0K | — | ||
| Q2 25 | $25.0K | $1.8B | ||
| Q1 25 | $16.0K | — | ||
| Q4 24 | $45.0K | $1.4B | ||
| Q3 24 | $35.0K | — | ||
| Q2 24 | $50.0K | $901.9M | ||
| Q1 24 | $40.0K | — |
| Q4 25 | $-4.2M | $877.2M | ||
| Q3 25 | $-3.3M | — | ||
| Q2 25 | $-2.8M | $414.8M | ||
| Q1 25 | $-3.7M | — | ||
| Q4 24 | $-6.0M | $865.6M | ||
| Q3 24 | $-3.7M | — | ||
| Q2 24 | $-1.8M | $-32.5M | ||
| Q1 24 | $-5.8M | — |
| Q4 25 | — | 89.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 89.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 90.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 89.4% | ||
| Q1 24 | — | — |
| Q4 25 | -14057.1% | 28.9% | ||
| Q3 25 | -9411.5% | — | ||
| Q2 25 | -10584.0% | 19.2% | ||
| Q1 25 | -22618.8% | — | ||
| Q4 24 | -13011.1% | 8.7% | ||
| Q3 24 | -12825.7% | — | ||
| Q2 24 | -7388.0% | -15.4% | ||
| Q1 24 | -14335.0% | — |
| Q4 25 | -19881.0% | 35.5% | ||
| Q3 25 | -12630.8% | — | ||
| Q2 25 | -11176.0% | 23.4% | ||
| Q1 25 | -23156.3% | — | ||
| Q4 24 | -13260.0% | 64.1% | ||
| Q3 24 | -10571.4% | — | ||
| Q2 24 | -3672.0% | -3.6% | ||
| Q1 24 | -14542.5% | — |
| Q4 25 | $-6.46 | $13.25 | ||
| Q3 25 | $1.57 | — | ||
| Q2 25 | $-3.68 | $6.32 | ||
| Q1 25 | $-0.05 | — | ||
| Q4 24 | $-21.80 | $13.33 | ||
| Q3 24 | $-6.00 | — | ||
| Q2 24 | $-3.00 | $-0.55 | ||
| Q1 24 | $-0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0M | $3.5B |
| Total DebtLower is stronger | $4.5M | — |
| Stockholders' EquityBook value | $-9.8M | $7.3B |
| Total Assets | $5.8M | $8.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | $3.5B | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $835.0K | $2.1B | ||
| Q1 25 | $2.2M | — | ||
| Q4 24 | $4.0M | $1.5B | ||
| Q3 24 | $7.2M | — | ||
| Q2 24 | $10.1M | $1.4B | ||
| Q1 24 | $10.9M | — |
| Q4 25 | $4.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.7M | — | ||
| Q1 25 | $2.4M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $3.3M | — | ||
| Q2 24 | $3.3M | $11.0M | ||
| Q1 24 | $3.3M | — |
| Q4 25 | $-9.8M | $7.3B | ||
| Q3 25 | $-6.1M | — | ||
| Q2 25 | $-6.5M | $6.1B | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $-1.3M | $5.5B | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | $6.1M | $4.3B | ||
| Q1 24 | $4.8M | — |
| Q4 25 | $5.8M | $8.7B | ||
| Q3 25 | $5.5M | — | ||
| Q2 25 | $4.1M | $7.2B | ||
| Q1 25 | $6.2M | — | ||
| Q4 24 | $8.6M | $6.2B | ||
| Q3 24 | $13.6M | — | ||
| Q2 24 | $15.7M | $4.8B | ||
| Q1 24 | $16.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.54× | 0.00× | ||
| Q1 24 | 0.69× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.0M | $323.3M |
| Free Cash FlowOCF − Capex | — | $322.4M |
| FCF MarginFCF / Revenue | — | 13.0% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | 0.37× |
| TTM Free Cash FlowTrailing 4 quarters | — | $594.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.0M | $323.3M | ||
| Q3 25 | $-5.1M | — | ||
| Q2 25 | $-1.5M | $361.8M | ||
| Q1 25 | $-2.4M | — | ||
| Q4 24 | $-4.0M | $41.9M | ||
| Q3 24 | $-3.1M | — | ||
| Q2 24 | $-3.0M | $-124.7M | ||
| Q1 24 | $-4.8M | — |
| Q4 25 | — | $322.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $356.6M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $40.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-125.5M | ||
| Q1 24 | — | — |
| Q4 25 | — | 13.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 20.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -13.9% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.87× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
